$SYRS
Syros Pharmaceuticals Inc.
PRICE
$0.6707 βΌ-3.566%
Delayed Price
VOLUME
200,233
DAY RANGE
-
52 WEEK
0.65 - 7.03
Key Metrics
Market Cap
43.69 M
Beta
1.74
Avg. Volume
864.06 K
Shares Outstanding
62.82 M
Yield
0%
Public Float
0
Next Earnings Date
2022-08-04
Next Dividend Date
Company Information
Syros is redefining the power of small molecules to control the expression of genes. Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop medicines that provide a profound benefit for patients with diseases that have eluded other genomics-based approaches. Syros is advancing a robust clinical-stage pipeline, including: SY-1425, a first-in-class oral selective RARΞ± agonist in RARA-positive patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide in patients with acute promyelocytic leukemia; and SY-5609, a highly selective and potent oral CDK7 inhibitor in patients with select solid tumors. Syros also has multiple preclinical and discovery programs in oncology and monogenic diseases.
CEO: Nancy Simonian
Website: syros.com
HQ: 35 Cambridge Park Drive Cambridge, 02140 Massachusetts
Related News